Nanomedicine is the application of nanotechnology for the diagnosis, prevention, and treatment of disease. This report will focus on the use of nanomedicines for drug delivery and therapeutic purposes, which are often referred to as nanopharmaceuticals, nanodrugs, or nanotherapeutics. Nanopharmaceuticals are defined as drugs or biologics that have been combined with certain synthetic or biological delivery systems, or nanocarriers, in order to impart physical and biological advantages over conventional medicines.
These include enhanced efficacy, reduced toxicity, improved solubility and stability, improved PK/PD, increased circulation time, targeted controlled release and tissue selectivity, and increased intracellular concentration.
The vast majority of marketed and pipeline nanopharmaceuticals are being used to treat a wide range of cancer indications, highlighting the ongoing unmet needs in this area. Other therapy areas include infectious diseases, cardiovascular (CV) and metabolic conditions, ophthalmology, and rare diseases.
A significant proportion of pipeline candidates are in Phase I or Phase II (65%), and almost 70% of the companies are either start-ups or small biopharmaceutical companies. This represents significant opportunities for mergers and acquisitions (M&As) or licensing agreements with larger pharmaceutical companies looking to either invest in innovative nanotechnology or bolster their pipelines with novel therapies.
Novel nanopharmaceuticals allow the implementation of personalized and precision medicine, particularly in cancer. This includes immunoconjugates and the use of nanomaterials as carriers for ribonucleic acid interference (RNAi)-based therapies. Some smart nanocarriers release a drug when triggered by internal or external stimuli, while nano-radioenhancers use the inherent properties of inorganic nanomaterials to treat tumors using local hyperthermia.
In the near future, nanopharmaceuticals will play a key role in the fight against the rise of chronic diseases due to the growing aging population. As well as cancer, this includes diabetes, arthritis, CV disease, Alzheimer’s disease, and Parkinson’s disease. There is a need for new treatments with reduced side effects that can improve quality of life (QoL), leading to improved patient outcomes, reduced burden on primary care, and reduced hospitalizations.
Nanomedicine also has the potential to combat the threat of antibiotic resistance via the use of nanomaterials with intrinsic antibacterial properties, as well as using nanoparticles as effective drug delivery systems for antibacterial agents.
The Nanopharmaceuticals report provides an assessment of the key industry trends impacting how nanopharmaceuticals are being used in healthcare today, including technological, regulatory, and macroeconomic themes.
Components of the report include -
- Key Industry Players - the big players in the nanopharmaceuticals industry and where they sit in the value chain.
- Trends in the nanopharmaceutical space - key trends impacting the use of nanopharmaceuticals classified into technology, macroeconomic, and regulatory themes.
- Industry Analysis - market value of marketed and pipeline nanopharmaceuticals to 2025, as well as a breakdown of nanopharmaceuticals by branded or generic product, phase of development, type of company, and route of administration. Key M&A and licensing agreements in the nanopharmaceutical space are also included, as well as case studies showing examples of the different types of nanopharmaceuticals and their application.
- Value Chain - Leaders and challengers by nanopharmaceutical type
Reasons to Buy
- Develop business strategies by understanding how nanotechnology is being used in the healthcare today and how this technology is expected to affect the healthcare sector in the future.
- Stay up to date on the industry’s big players in nanopharmaceuticals and where they sit in the value chain.
- Identify emerging industry trends to gain a competitive advantage.
- Identify pipeline targets for M&A and licensing opportunities.
Table of Contents1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Industry Players
3 Industry Trends
3.1 Technology Trends
3.2 Macroeconomic Trends
3.3 Regulatory Trends
3.4 Expected Impact of Nanomedicines on the Biopharmaceutical Industry in 2020
4 Industry Analysis
4.1 Market Size and Growth Forecasts
4.2 Marketed Nanopharmaceuticals
4.3 Pipeline Nanopharmaceuticals
4.4 Mergers, Acquisitions, and Strategic Alliances
4.6 Case Studies
4.6.1 Targeting Liver Cells with Diasome’s Liposomal Additive Improves the Efficacy and Safety of Insulins
4.6.2 PharmaCyte’s Polymer-Based Cell-in-a-Box Technology Allows the Administration of Lower Doses of Chemotherapy
4.6.3 Kala Pharmaceuticals’ Nanocrystal-Based AMPPLIFY Technology Allows Drug Particles to Penetrate Mucus Barriers and Significantly Increase Drug Delivery to Target Eye Tissues
4.6.4 Celgene’s Abraxane, an Albumin-Bound Nanoformulation of Paclitaxel, Reduces the Toxicity Associated with Its Free Form
4.6.5 Oasmia Pharmaceuticals’ XR17 Micelle Technology Allows for Shorter Infusions of Chemotherapy with No Premedication Required
4.6.6 Alnylam’s Onpattro, Based on Lipid Nanotechnology, Is the First RNAi Therapeutic to Receive Approval
4.6.7 Starpharma’s Dendrimer-Based DEP Technology Improves Efficacy and Reduces Toxicity Associated with Leading Chemotherapy Drugs
4.6.8 Nanobiotix’s Hensify, a First-in-Class Radioenhancer, Utilizes Inorganic Hafnium Oxide Nanoparticles to Amplify the Effects of Radiation Treatment
4.6.9 Daiichi Sankyo’s Antibody-Drug Conjugate Enhertu Offers a Novel Treatment Option for Metastatic Breast Cancer
5 Value Chain
5.1.1 Liposomal Nanoparticles
5.1.2 Polymeric Nanoparticles
5.1.4 Protein Nanoparticles
5.1.5 Lipid Nanoparticles
5.1.8 Inorganic Nanoparticles
6.1 Public Companies
6.2 Private Companies
List of Tables
Table 1: Technology/Scientific Trends
Table 2: Macroeconomic Trends
Table 3: Regulatory Trends
Table 4: M&As in the Nanopharmaceutical Industry
Table 5: Strategic Alliances in the Nanopharmaceutical Industry
Table 6: Approved Liposomal Nanopharmaceuticals in the US and Europe
Table 7: Polymeric Nanopharmaceuticals in Development
Table 8: Approved Nanocrystal Nanopharmaceuticals in the US and Europe
Table 9: Nanocrystal Nanopharmaceuticals in Development
Table 10: Approved Protein-based Nanopharmaceuticals in the US and Europe
Table 11: Lipid Nanopharmaceuticals Approved in the US and Europe
Table 12: Lipid Nanopharmaceuticals in Development
Table 13: Micelle-Based Nanopharmaceuticals Approved in the US and Europe
Table 14: Micelle-Based Nanopharmaceuticals in Development
Table 15: Dendrimer-Based Nanopharmaceuticals Approved in the US and Europe
Table 16: Dendrimer-Based Nanopharmaceuticals in Development
Table 17: Inorganic Nanopharmaceuticals in Development
Table 18: Approved Immunoconjugates in the US and Europe
Table 19: Immunoconjugates in Development
Table 20: Nanoemulsions Approved in the US and Europe
Table 21: Nanoemulsions in Development
Table 22: Public Companies
Table 23: Private Companies
List of Figures
Figure 1: The Leaders and Challengers in the Nanopharmaceutical Value Chain
Figure 2: Pharma Executives Do Not Expect Nanomedicine to Have a High Impact on the Industry in 2020
Figure 3: Market Forecast by Nanopharmaceutical Type, 2018-2025
Figure 4: 2025 Market Value by Nanopharmaceutical Type
Figure 5: 2025 Market Value by Branded or Generic/Biosimilar Nanopharmaceuticals
Figure 6: Approved Nanopharmaceuticals in the US and Europe by Type and Therapy Area
Figure 7: Route of Administration of Marketed Nanopharmaceuticals
Figure 8: Nanopharmaceuticals in Development by Type, Therapy Area, and Route of Administration
Figure 9: Nanopharmaceuticals by Current Development Stage, and Estimated 2025 Market Revenue by Current Development Stage
Figure 10: Nanopharmaceuticals in Development by Company Type and Molecule Type
Figure 11: Timeline
Figure 12: Diasome’s Nanoscale, Frisbee-shaped HDV Carrier
Figure 13: PharmaCyte’s Cell-in-a-Box Technology
Figure 14: Traditional Suspension of Eye Drops Versus Kala Pharmaceuticals’ MPP Technology
Figure 15: Oasmia Pharmaceuticals’ XR17 Micellar Technology Platform
Figure 16: Arbutus Biopharma’s LNP Technology, Which Was Used to Develop Alnylam’s Onpattro
Figure 17: Structure of DEP Docetaxel (left), and Pharmacokinetics of DEP Docetaxel Versus Conventional Docetaxel (right)
Figure 18: Nanobiotix’s Hensify Technology
Figure 19: Daiichi Sankyo’s Enhertu Is an ADC Delivering Cytotoxic Drug to Target Cancer Cells
Figure 20: The Nanopharmaceutical Value Chain
Figure 21: The Liposomal Nanopharmaceutical Value Chain
Figure 22: The Polymeric Nanopharmaceutical Value Chain
Figure 23: The Nanocrystal Nanopharmaceutical Value Chain
Figure 24: The Protein-Based Nanopharmaceutical Value Chain
Figure 25: The Lipid Nanopharmaceutical Value Chain
Figure 26: The Micelle Nanopharmaceutical Value Chain
Figure 27: The Dendrimer Nanopharmaceutical Value Chain
Figure 28: The Inorganic Nanopharmaceutical Value Chain
Figure 29: The Immunoconjugate Value Chain
Figure 30: The Nanoemulsion Value Chain
Figure 31: Five-Step Approach for Generating a Sector Scorecard